Ipsen Group Overview

  • Founded
  • 1929
Founded
  • Status
  • Public
  • Employees
  • 5,807
Employees
  • Stock Symbol
  • IPN
Stock Symbol
  • Investments
  • 23
  • Share Price
  • $88.95
  • (As of Tuesday Closing)

Ipsen Group General Information

Description

Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: specialty care and primary care. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focus on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Other Commercial Services
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
PAR
Primary Office
  • 65, quai Georges Gorse
  • 92100 Boulogne Billancourt
  • France
+33 01 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ipsen Group Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$88.95 $85.74 $37.48 - $113.19 $7.36B 82.7M 126K -$0.65

Ipsen Group Financials Summary

In Thousands,
USD
TTM 30-Jun-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 7,554,844 8,328,283 10,595,811 10,047,191
Revenue 2,993,342 3,014,329 2,771,268 2,268,724
EBITDA 181,810 129,296 757,957 546,402
Net Income (54,079) (56,756) 459,636 307,090
Total Assets 4,757,128 4,824,469 3,863,418 3,685,486
Total Debt 1,106,450 955,843 383,894 434,532
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ipsen Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ipsen Group‘s full profile, request access.

Request a free trial

Ipsen Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, e
Other Commercial Services
Boulogne Billancourt, France
5,807 As of 2019
00000
00000000000 00000

00000000

reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaeca
000000000000000
Leiden, Netherlands
000 As of 0000
00000
000000000 00000

00000000

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
000000000000000
Milan, Italy
0000 As of 0000
0.000 0000-00-00
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ipsen Group Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pharming Group Formerly VC-backed Leiden, Netherlands 000 00000 000000000 00000
000000000 Private Equity-Backed Milan, Italy 0000 000000000000
000000 00000000000 Corporation Parma, Italy 0000
000000 Corporation Paris, France 000000 000000000000
00000 000000000000 Private Equity-Backed Atlanta, GA 000 000.00 0&0
You’re viewing 5 of 37 competitors. Get the full list »

Ipsen Group Executive Team (27)

Name Title Board Seat Contact Info
Richard Paulson Executive Vice President & Chief Executive Officer, North America
David Loew Chief Executive Officer & Board Member
Aymeric Le Chatelier Executive Vice President & Group Chief Financial Officer
Priyanka Rohatgi Ph.D Managing Director, Ipsen Ventures
Dominique Laymand Executive Vice-President & Chief Ethics and Compliance Officer
You’re viewing 5 of 27 executive team members. Get the full list »

Ipsen Group Board Members (7)

Name Representing Role Since
0000 00000000 Ipsen Group Board Member 000 0000
00000 0000 Ipsen Group Chief Executive Officer & Board Member 000 0000
00000 00000000 Self Board Member 000 0000
0000 00 0000000 Self Chairman of the Board of Directors 000 0000
0000000 000000 Ipsen Group General Secretary & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Ipsen Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ipsen Group Investments & Acquisitions (23)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 18-Apr-2019 000000000000000000 00.000 Biotechnology 00000 0000
000000 (0000 00000 08-May-2017 000000000 00000 00 000.00 Buildings and Property 00000 0000
000000000 00000000 03-Apr-2017 000000000 00000 00 00.000 Buildings and Property 00000 0000
000000 00000000000 16-Feb-2017 000000000 0000 Biotechnology
Akkadeas Pharma 31-Jan-2017 Secondary Transaction - Private Food Products
You’re viewing 5 of 23 investments and acquisitions. Get the full list »

Ipsen Group Subsidiaries (4)

Company Name Industry Location Founded
Clementia Pharmaceuticals Biotechnology Montreal, Canada 2010
000000 00000000000 Drug Discovery London, United Kingdom 0000
00000 000000000000 Biotechnology Basking Ridge, NJ 0000
00000 00000000 Venture Capital Boulogne Billancourt, France
To view Ipsen Group’s complete subsidiaries history, request access »

Ipsen Group Exits (6)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 16-Feb-2017 000000000 0000 Completed
  • 7 buyers
00000 000000000000 13-Aug-2015 00000 00000 00 0000 Completed
  • 8 buyers
000000 00000000000 13-Aug-2015 00000 00000 00 0000 Completed
  • 8 buyers
000000 00000000000 29-Jul-2013 00000 00000 00 0000 Completed
  • 7 buyers
Radius Health 16-Dec-2011 Later Stage VC 000.00 Completed
  • 10 buyers
You’re viewing 5 of 6 exits. Get the full list »